A cellulose-containing article for treating an area of skin, wherein the article comprises BNC in an amount of at least 1% by weight and at most 15% by weight, comprises fluid in an amount of at least 85% by weight and at most 99% by weight, has an average thickness of at least 0.5 mm and at most 8 mm, wherein the BNC is of microbial origin.

A transdermal delivery device for dispensing personalized transdermal dosage formulations from a plurality of reservoirs, and a personalized method for producing the transdermal delivery device. A prescription fill service receives electronic prescription data for a plurality of transdermal dosage formulations to be administered to a given patient. The prescription fill service deposits transdermal dosage formulations in two or more reservoirs of a transdermal device substrate via 3D printing of printable pharmaceutical agent. The electronic prescription data may include transdermal dosage formulations data used to select printable pharmaceutical agent deposited in respective reservoirs. The electronic prescription data further may include medication regimen data for administration of transdermal medications, such as timing data for release of selected transdermal dosage formulations. In an embodiment, a finished transdermal delivery device includes barriers formed at reservoir openings, a controller, and a controlled energy source that degrades the barriers to actuate release of reservoir contents.

A system is disclosed for delivery of a therapeutic agent to a site in mucosal tissue or to the skin of a patient. The system includes a porous mucoadhesive, freeze-dried matrix formed by a composition including chitosan in an aqueous salt solution of a chloride salt of a monovalent cation. The system further includes a plurality of chitosan microparticles having an average diameter between 500 nm and 2000 nm and comprising a therapeutic agent.

The present invention provides compositions useful in reducing, ameliorating, and/or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing, ameliorating, and/or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration, or periodic administration.

a film composite for manufacturing a package for planar carriers of pharmaceutical active substances, for example transdermal patches, encompassing, in a direction from the outer side of the film composite toward its inner side: a metal layer; an acrylic-acid-containing joining layer; a polyethylene layer; and a COC layer made of cycloolefin copolymer, a side of the COC layer which faces away from the metal layer being an exposed surface of the film composite, wherein provision is made that the polyethylene layer encompasses metallocene polyethylene.

Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof.

The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.

The purpose of the present invention is to provide an aqueous patch in which basic physical properties as an aqueous patch are less likely to deteriorate and crystals of 1-menthol are less likely to precipitate. The aqueous patch includes, in a pasty preparation, 1-menthol: 0.5% by mass or more and 10% by mass or less, an oil component: 0.2% by mass or more and 19% by mass or less; and silica: 0.1% by mass or more and 5.5% by mass or less.

The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.